These results are also consistent with a previous study that found a downtrend of the E5 antigen as the lesions progress to cancer (LSIL, 80%; SCC, 60%) [26], which is a similar trend to that observed with anti-E5 antibodies and the degree of cervical lesions in our study. Here, ARHGEF15 is linked to cancer.